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Abstract
Background: The negative consequences of nicotine use are well known and documented, however, abstaining
from nicotine use and achieving abstinence poses a major challenge for the majority of nicotine users trying to
quit. l-Tetrahydropalmatine (l-THP), a compound extracted from the Chinese herb Corydalis, displayed utility in the
treatment of cocaine and heroin addiction via reduction of drug-intake and relapse. The present study examined
the effects of l-THP on abuse-related effects of nicotine.
Methods: Self-administration and reinstatement testing was conducted. Rats trained to self-administer nicotine
(0.03 mg/kg/injection) under a fixed-ratio 5 schedule (FR5) of reinforcement were pretreated with l-THP (3 or
5 mg/kg), varenicline (1 mg/kg), bupropion (40 mg/kg), or saline before daily 2-h sessions. Locomotor, food, and
microdialysis assays were also conducted in separate rats.
Results: l-THP significantly reduced nicotine self-administration (SA). l-THP’s effect was more pronounced than
the effect of varenicline and similar to the effect of bupropion. In reinstatement testing, animals were pretreated
with the same compounds, challenged with nicotine (0.3 mg/kg, s.c.), and reintroduced to pre-extinction conditions.
l-THP blocked reinstatement of nicotine seeking more effectively than either varenicline or bupropion. Locomotor data
revealed that therapeutic doses of l-THP had no inhibitory effects on ambulatory ability and that l-THP (3 and 5 mg/kg)
significantly blocked nicotine induced hyperactivity when administered before nicotine. In in-vivo microdialysis
experiments, l-THP, varenicline, and bupropion alone elevated extracellular dopamine (DA) levels in the nucleus
accumbens shell (nAcb).
Conclusions: Since l-THP reduces nicotine taking and blocks relapse it could be a useful alternative to varenicline and
bupropion as a treatment for nicotine addiction.
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Background
Nicotine addiction via tobacco smoking can lead to
cancer and is a leading cause of preventable, premature
death [2, 1]. This correlation is well known and docu-
mented, however, according to the Center for Disease
Control and Prevention there are currently 42.1 million
smokers in the U.S. [5]. A large majority of these users
(70 %) have the desire to quit smoking [2], but an in-
ability to do so. Nicotine elicits its effect on users by
binding to nicotinic acetylcholine receptors (nAChRs),
which are found in the central as well as the peripheral
nervous system [2, 7, 13]. nAChRs located in the ven-
tral tegmental area (VTA) and nAcb modulate the re-
lease of DA in the mesolimbic DA system, triggering the
reward and reinforcement of nicotine use [2, 12, 23, 24].
This reward incites the nicotine addiction cycle that can
be highly difficult to break.
A variety of treatments are currently on the market to
treat nicotine addiction including bupropion, varenicline,
and nicotine replacement therapy [2, 22]. Bupropion acts
by blocking the reuptake of DA/norepinephrine (NE)
from the synapse alleviating the hypodopaminergic state
associated with craving. Varenicline acts by binding
nAChRs as a partial agonist, stimulating modest release
of DA to alleviate the hypodopaminergic state [4, 6, 9].
Varenicline also acts as a competitive antagonist when
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given in the presence of nicotine. Both varenicline and
bupropion, however, carry black box warnings for neuro-
psychiatric symptoms and suicidality [2]. Nicotine re-
placement therapy administers low concentrations of
nicotine transdermally or via GI absorption relieving the
hypodopaminergic state without creating the addictive
euphoria of smoking a cigarette [2]. Despite these inter-
ventions, the effectiveness of smoking cessation in clin-
ical trials with these treatments only reaches a success
rate of 5 to 35 % [2]. Thus, the current treatments for
nicotine addiction have limited effectiveness and side-
effects that make the continued research and develop-
ment of new anti-smoking therapeutics a necessity.
l-THP, is a purified compound from the Chinese plant
Corydalis, and has been used safely for decades in China
to treat chronic pain as a non-opioid analgesic [17, 19,
20, 30, 34]. l-THP has a favorable safety profile, as com-
mon adverse events seen in its clinical use are sleepiness,
dizziness, and nausea [30]. The therapeutic potential of
this herbal compound has been explored to include anti-
addiction treatments for cocaine, methamphetamine,
and heroin [19, 20, 28, 30, 34]. In the preclinical setting,
l-THP has been shown to effectively reduce cocaine SA
and methamphetamine reward as assessed by condition
place preference testing [19, 20, 28, 31]. This efficacy is
translated to the clinical setting as l-THP has been
shown to reduce craving and relapse to heroin-seeking
when given after detoxification [33]. The mechanism of
action of l-THP is not completely known. However, it is
known that l-THP binds to D1, D2, D3, serotonin (5-
HT), and alpha-1 adrenergic receptors antagonistically,
while binding to alpha-2 adrenergic receptors as an
agonist [17, 30]. This broad binding profile of l-THP is
believed to underlie its utility in the treatment of addic-
tion to various classes of drugs. The utility seen in pre-
vious studies of l-THP as an aid in the treatment of
psychostimulant and opioid addiction warrants further
study of the efficacy of l-THP on the abuse-related
effects of other drugs within these classes.
In the current study, we examined the efficacy of l-
THP in the treatment of various behavioral models of
nicotine addiction as assessed by nicotine SA, re-
instatement, and locomotor hyperactivity in rats. The
efficacy of l-THP in the treatment of nicotine SA was
systematically compared with the efficacy of FDA-
approved anti-smoking medications, bupropion and
varenicline. This was done with the aim of making a
case for clinical study of l-THP in the treatment of
nicotine addiction. As a separate analysis, we also con-
ducted in vivo microdialysis experiments that studied
the effect of l-THP administration on extracellular DA
concentrations within the nucleus accumbens shell;
this effect of l-THP was compared to the effects of
nicotine, as well as combinations of l-THP and
nicotine, bupropion and nicotine, and varenicline and
nicotine. This is the first report to provide behavioral




Nicotine hydrogen tartrate salt (Sigma Aldrich, St. Louis,
MO) was dissolved in 0.9 % NaCl (Hospira, Inc, Lake
Forest, IL) with pH adjusted to 7 using sodium hydrox-
ide. l-THP (base), was acquired from Wuxi Gorunje
Technology Co., LTD and was dissolved in 2 % tween 80
(Sigma Aldrich, St. Louis, MO), 3 % ethanol (Sigma
Aldrich, St. Louis, MO), and 95 % sterile water (Hospira,
Inc, Lake Forest, IL). The reported purity of l-THP was
assessed by high performance liquid chromatography
where the purity was determined as 98.85 %. Varenicline
tartrate was supplied by LKT Laboratories, Inc and dis-
solved in 0.9 % NaCl with pH adjusted to 7 using sodium
hydroxide. Bupropion was supplied by Enzo Life Sciences
and dissolved in 0.9 % NaCl. 3-Hydroxytyramine (3,4 Dihy-
droxyphenethylamine; Dopamine Hydrochloride) (Sigma
Aldrich, St. Louis, MO) was diluted to 10−8 with Perchloric
Acid 70 % (Sigma Aldrich, St. Louis, MO) and sterile water
(Hospira, Inc, Lake Forest, IL). Ketamine HCl was
supplied through NIDA pharmacy. Xylazine (Sigma
Aldrich, St. Louis, MO) was dissolved in 0.9 % NaCl.
Equithesin (Pentobarbital Na, Chloral hydrate and Magne-
sium Sulfate) was supplied by NIDA. Formalin Solution
10 % was acquired from Sigma Aldrich, St. Louis, MO.
Animals
For the behavioral experiments, male Sprague-Dawley
rats (Charles River) weighing 300–325 g at the beginning
of the study were individually housed and maintained in
temperature- and humidity-controlled facilities fully
accredited by AAALAC. Animals were housed on a
12 h/12 h dark/light cycle (lights out from 8:00 am to
8:00 pm). Behavioral experiments were conducted in the
dark phase. For the microdialysis experiments, male
Sprague-Dawley rats (Charles River) weighing 200–
275 g at the beginning of the study were housed two to
a cage and maintained in temperature- and humidity-
controlled facilities fully accredited by AAALAC.
Animals were housed on a 12 h/12 h light/dark cycle
(lights out from 8:00 pm to 8:00 am). Microdialysis
experiments were conducted in the light phase. All ex-
perimental procedures were approved and conducted in
accordance with guidelines of the Institutional Animal
Care and Use Committee of the Intramural Research
Program National Institute on Drug Abuse, National
Institutes of Health, Department of Health and Human
Services and the University of Maryland, Baltimore. All
treatment groups were randomly assigned for each
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study. Only animals meeting the specified criteria per
experiment were analyzed.
Nicotine SA and reinstatement
Catheterization surgery
Jugular vein catheter implantations were performed as
described previously [27]. Briefly, rats were anesthetized
under ketamine/xylazine (100 mg/kg, 10 mg/kg), and
implanted with a catheter in the jugular vein and a
mesh-based backmount just below the shoulder blades.
Rats were allowed to recuperate for at least five days.
Nicotine SA
After the recuperation period, rats began SA training
(Coulbourn Instruments, Whitehall, PA). Rats were
placed on a restricted diet of chow per day (~30 g) to
maintain their current weight. During 2-h training ses-
sions, nose pokes to the correct hole resulted in an in-
fusion (Harvard Apparatus, Holliston, MA) of 0.03 mg/kg
nicotine, followed by a 20-s timeout period in which
house lights flashed on and off. Training began under a
fixed-ratio (FR) 1 schedule of reinforcement. Once a rat
received at least 10 reinforcers for three consecutive ses-
sions, the response criteria was increased incrementally to
FR 2, FR 3, and finally FR 5. Once a rat responded at or
above 10 infusions for five consecutive sessions, pre-
treatment with saline (i.p. 30 min), l-THP (3 mg/kg,
5 mg/kg i.p. 30 min), varenicline (1 mg/kg i.p. 2-h), or
bupropion (40 mg/kg i.p. 30 min) began. Repeated test-
ing consisted of three consecutive days during which
rats were pretreated with one of the aforementioned
drugs and allowed to self-administer nicotine during 2-
h sessions. Separate rats were used for dosing groups.
Nicotine extinction
Extinction occurred in the same chambers as SA by re-
moving nicotine-associated cues and replacing saline in-
fusions for nicotine. Thus the infusion and 20-s timeout
did not occur after the FR 5 criterion was met. Rats were
trained under extinction criteria for at least five sessions
or until responding was at or below 25 % of nicotine
baseline responding. Once this criterion was met, re-
instatement testing began.
Nicotine reinstatement
Rats were pretreated with saline (i.p.), l-THP (3 mg/kg,
5 mg/kg i.p.), varenicline (1 mg/kg i.p.), or bupropion
(40 mg/kg i.p.) 30 min before placement into chambers
and received nicotine (0.3 mg/kg s.c.) 5 min before
placement into chambers. Environmental cues present
during nicotine SA (20 s time out, infusion of pump)
were reintroduced. During reinstatement sessions nico-
tine was not available, infusions of 0.03 ml/kg saline
were delivered after the FR 5 criterion was met.
Nicotine-induced hyperactivity testing
Nicotine-induced hyperactivity testing was conducted over
the course of 14 one-hr sessions. Rats were allowed to ac-
climate to the chambers for two sessions. Baseline readings
with injections of saline 30 min and 5 min before access to
locomotor chambers were taken for four sessions. On the
seventh session, pretreatment with either l-THP (3 mg/kg,
5 mg/kg i.p.) or saline (i.p.) was given 30 min before place-
ment into the chamber followed by an injection of 1 ml/kg
saline (s.c.) 5 min before the start of the session. During
sessions 8–13 rats were pretreated with l-THP or saline
30 min before the start of the session, followed by and in-
jection of 0.4 mg/kg nicotine (s.c.) 5 min before the start of
the session. In session 14 (Nic Challenge) rats received only
a challenge dose of 0.4 mg/kg nicotine five minutes before
the start of the session.
l-THP locomotor control
Rats were allowed two sessions to acclimate to loco-
motor chambers (Med Associates Inc, Georgia, VT).
After the acclimation period, rats were pretreated with
saline or l-THP (3, 4, 5 mg/kg i.p.) 30 min before loco-
motor sessions began. Rats received an injection of
1 ml/kg saline (s.c.) 5 min before placement into loco-
motor chambers. This delivery method of treatments
was done to mirror injections given during hyperactivity
testing. Rats were then allowed to move freely in loco-
motor chambers for 1-h sessions.
l-THP food reward control
Food reward studies were conducted in behavioral
chambers (Med Associates Inc, St. Albans, VT) on a sep-
arate group of rats. Rats were again food restricted to
maintain their present weight. Rats were trained to nose
poke under an FR 10 schedule for a delivery of sucrose
pellets (Bioserv, Flemington, NJ). Sessions timed out
after 1-h, 20-s time outs occurred after each pellet deliv-
ery. Once animals received the maximum number of
pellets in the session (40 pellets) for three consecutive
sessions, l-THP testing began. Rats were pretreated with




Microdialysis surgeries were performed as described previ-
ously [29] in a separate group of rats. Briefly, rats were
anesthetized under Equithesin (20 mg/kg) and probes made
of 22 g 1/2 needles with 8 mm silica, and 2 mm exposed
membrane were implanted into the shell of the nucleus ac-
cumbens (A +2 mm, L +1 mm from bregma, V-8 mm to
dura). Rats were placed in individual hemispheric bowls to
recuperate. Experiments were performed the following day
to minimize surgery-induced neurotransmitter release.
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Microdialysis procedure
Microdialysis experiments were performed in the same
hemispheric bowls in which rats stayed overnight. Rats
were connected to pumps (Bioanalytical Systems Inc,
W. Lafavette, IN) with ringer solution (sodium chloride:
calcium chloride: potassium chloride, filtered with
25 mm 0.2um syringe filter) infused at a flow rate of 1
ul/min. DA 10−8M was used as an external standard
and was tested at least twice immediately before baseline
measures were taken to ensure 10 % or less variability in
the system (peak of the standard concentration was 100
fmol/min). Baseline DA measures were taken every
20 min until three consecutive samples displayed variabil-
ity of no more than 17 %. Once this criterion was met, rats
were given 5 mg/kg l-THP (i.p.) or 0.4 mg/kg nicotine
(s.c.) (control groups); or pretreated with 5 mg/kg l-
THP, 40 mg/kg bupropion (i.p.) (40 min), or 1 mg/kg
varenicline (i.p.) (2-h) then given 0.4 mg/kg nicotine
(s.c.). Dialysis samples were taken every 20 min over 3-
h post nicotine injection. Samples were injected with-
out extraction or purification into Dionex UltiMate 3000
HPLC (Chelmsford, MA) coupled to ESA Coulochem III
electrochemical detector (Chelmsford, MA), monoso-
diumphosphate buffer in methanol/water (10:74:16, v/v/v).
Histology
At the end of microdialysis experiments, rats were over-
dosed with phenobarbital. Probes were removed and
brains fixed in 20 % formalin for at least two weeks.
Brains were cut by vibratome 1000 plus (The vibratome
company, St. Louis, MO) into serial coronal slices of
1 cm thickness to verify the placement of probes. Inden-
tation marks left from probes were observed to ensure
probe placement was within the nucleus accumbens.
Statistics
Statistical analysis was carried out by GraphPad 5.00 for
windows (La Jolla, CA). Student’s t-test, one-way or two-
way ANOVA was used to assess significance according
to experimental design. When appropriate one or two-
way ANOVA was followed by Bonferroni post hoc test of
significance. Significance was reported at p < 0.05 or
lower. All analysis was performed on the raw data. For
data presentation, a percent of control measure was used
to display the observed effects of compounds on SA and
reinstatement testing. The percent of control was calcu-
lated by taking the three day mean of each individual rat
within the same treatment group and dividing it by the
three day mean of the entire treatment group during
nicotine baseline. In SA testing the test average is pre-
sented as a percentage of nicotine baseline response. In
reinstatement testing extinction and reinstatement are
displayed as a percentage of nicotine baseline response.
Results
Effect of l-THP on nicotine SA
To assess the efficacy of l-THP in treatment of nicotine
addiction, naive rats were trained to self-administer
nicotine under an FR of 5. Rats were treated with saline
(1 ml/kg i.p.) or l-THP (3 mg/kg or 5 mg/kg, i.p.) before
placement into SA chambers. Both doses of l-THP dis-
played a trend of lowering the amount of nicotine infu-
sions taken per session; however, only 5 mg/kg l-THP
was statistically significant. Figure 1a and Additional file 1:
Figure S1a) displays the effects of l-THP on nicotine SA
over the testing period. Two-way ANOVA for repeated
measurements was used to analyze the data with defining
factors of pretreatment (saline v. 3 mg/kg l-THP v. 5 mg/
kg l-THP) and session (nic baseline v. test avg). There was
a significant effect of session [F (1, 21) = 6.871, p < 0.05].
The test average of 5 mg/kg l-THP was significantly
reduced in comparison to its nicotine average (t-test,
p <0.001).
Effects of varenicline and bupropion on nicotine SA
and comparison with l-THP
A separate group of rats were treated with varenicline
(1 mg/kg) or bupropion (40 mg/kg) before placement into
SA chambers. Figure 1b and Additional file 1: Figure S1b)
displays that like l-THP, these treatments significantly re-
duced nicotine SA. Two-way ANOVA for repeated mea-
sures was used with the defining factors of pretreatment
(saline v. 5 mg/kg l-THP v. 1 mg/kg varenicline v. 40 mg/
kg bupropion) and session (nic baseline v. test avg). A sig-
nificant effect of interaction between pretreatment and ses-
sion F(3,20) = 6.725, p < 0.01; and session F(1,20) = 38.39,
p < 0.001, was observed. Bonferroni post hoc analysis re-
vealed a significant effect of 5 mg/kg l-THP (p < 0.001),
1 mg/kg varenicline (p < 0.05) and 40 mg/kg bupropion
(p < 0.001) compared to saline treatment. Student’s t-
test analysis revealed that l-THP reduced nicotine in-
fusions significantly greater than varenicline (p <0.05)
and equal to bupropion. In a breakdown of testing over the
three day period (Fig. 1c and Additional file 1: Figure S1c),
two-way ANOVA revealed a significant effect of pretreat-
ment, F(3,40) = 11.89, p < 0.001. In Bonferroni post hoc
analysis, l-THP significantly reduced the number of
nicotine infusions taken each day (p < 0.01 days 1 and 2,
p < 0.001 day 3). Varenicline significantly reduced nicotine
infusions on days 2 and 3 (p < 0.05). Bupropion, displayed
varying significance in blocking nicotine infusions across
test days (p < 0.001 day 1, p < 0.01 day 2, p < 0.05 day 3).
Effect of l-THP on combined cue and nicotine-induced
reinstatement of drug-seeking
At the completion of SA testing, extinction was imposed.
Rats responded at low levels, below 25 % of nicotine base-
line responding within 10 sessions. Reinstatement testing
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was used to illustrate the effect of l-THP and other pre-
treatments on the prevention of relapse to nicotine-
seeking behavior. Figure 2 and Additional file 1: Figure S2
illustrates that pretreatment with both doses of l-THP sig-
nificantly blocked reinstatement to previous nicotine-
seeking behavior while pretreatment with saline did not, a
significant effect of interaction between session (baseline v.
extinction v. reinstatement) and pretreatment F(8, 50) =
7.075, p < 0.0001 and session was revealed, F(2,50) = 128.4,
p < 0.0001.
Effects of varenicline and bupropion on combined cue
and nicotine-induced reinstatement and comparison with
l-THP
Rats treated with varenicline and bupropion under-
went extinction in the same manner. When tested
under reinstatement conditions, both drug treatments
significantly blocked reinstatement to previous
nicotine-seeking behavior. Bonferroni post hoc ana-
lysis, from the reported two-way ANOVA analysis on
reinstatement testing, revealed significant differences
Fig. 1 Effect of l-THP on nicotine SA and comparison to varenicline and bupropion. l-THP decreased nicotine SA in animals trained to stably
respond for nicotine infusions. Each pretreatment was tested for three consecutive days all data is presented as mean + S.E.M. a Infusions per
session over five days of training (Nic Baseline) and three days of treatment (Test Avg) respectively. Saline demonstrated no effect on nicotine
SA, while l-THP at 5 mg/kg displayed a significant effect on nicotine responding. ***p < 0.001, t-test between test avg and nic baseline, n = 6
per group, 3 mg/kg l-THP group n = 12. b Infusions per session averaged in the same manner as the previous panel. l-THP, varenicline, and bupropion
significantly reduced nicotine responding compared to respective nicotine baselines, two-way ANOVA **p < 0.01, ***p < 0.001. + denotes comparison
of test averages to 5 mg/kg l-THP; the test average of 5 mg/kg l-THP was significantly lower than that of varenicline and saline, +p < 0.05, ++
+p < 0.001, n = 6 per group. All groups rebounded to baseline responding for nicotine in post test sessions. c Session breakdown of pretreatment
across three day repeated testing of nicotine SA. 5 mg/kg l-THP and 1 mg/kg varenicline performed stably across the three day test
period while 40 mg/kg bupropion did not, two-way ANOVA with Bonferroni post hoc analysis, all treatment groups were compared to
saline treatment, *p < 0.05, **p < 0.01, ***p < 0.001
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in nicotine baseline (Nic Baseline) and reinstatement
for varenicline and bupropion, p < 0.01 and p < 0.05
respectively. In comparison to bupropion and vareni-
cline, l-THP pretreatment, both 3 mg/kg and 5 mg/kg
performed superiorly, as seen in Fig. 2. Bonferroni post
hoc analysis revealed a significant difference in nico-
tine baseline and reinstatement for both l-THP doses,
p < 0.001.
Effect of l-THP on nicotine-induced hyperactivity
The psychostimulant effects of nicotine can manifest in
the form of locomotor hyperactivity. Locomotor activity
testing was conducted to assess the effect of l-THP on
nicotine induced hyperactivity. l-THP significantly re-
duced nicotine-induced hyperactivity when administered
as a pretreatment in the nicotine administration phase
as shown in Fig. 3a and b, two-way ANOVA revealed an
effect of pretreatment [F (2, 231) = 5.412, p < 0.01, n =
24] and session (baseline v. nicotine administration v.
nicotine challenge) [F (2,231) = 17.22, p < 0.0001, n = 24].
Saline did not block nicotine-induced hyperactivity.
Bonferroni post hoc analysis revealed significant differ-
ences between l-THP and saline treated animals (p <
0.001) during nicotine administration. When l-THP was
removed on test day, previous l-THP treated animals that
displayed no hyperactivity, rebounded to display hyper-
activity comparable with saline treated animals (t-test ana-
lysis of l-THP baseline and l-THP test-day yielded a
significance of p < 0.001).
Effect of l-THP on locomotor activity
Given the potential for l-THP to induce inhibitory ef-
fects, it was crucial to ensure that the therapeutic doses
of l-THP concerning nicotine addiction did not create
sedative effects. To this end, the effect of l-THP alone
on locomotor activity was tested. Figure 4a displays that l-
THP alone in the therapeutic range of 3–5 mg/kg did not
affect locomotor activity. No significant difference was
found between the mean distance traveled by animals pre-
treated with l-THP or saline (all p’s > 0.14). See Additional
file 1: Figure S3 for comparison of l-THP vehicle to saline.
Effect of l-THP on food-maintained behavior
To further ensure sedative effects of l-THP were not
observed within our therapeutic range, we evaluated
the effect of l-THP on operant responding for food.
Figure 4b displays that l-THP in the therapeutic range
of 3–5 mg/kg did not produce inhibitory effects on nat-
ural reward (food-sucrose pellets). No significant differ-
ence in responding for pellets compared to saline
pretreatment was found in this treatment range. Doses
greater than 5 mg/kg significantly reduced the rate of
responding for sucrose pellets one-way ANOVA [F(4, 36)
= 2.909, p < 0.01]. These results further validate that be-
havioral changes observed with 5 mg/kg l-THP pretreat-
ment were not a result of disruptive effects of l-THP on
operant behavior in general.
Effects of l-THP, varenicline, and bupropion on
extracellular DA levels in the nucleus accumbens shell
In a separate group of rats, microdialysis probes were
implanted in the nAcb (see Additional file 1: Figure S4)
to gain an understanding of the neurochemical changes
of DA that occur during administration of l-THP, vareni-
cline, and bupropion in the presence of nicotine. Base-
line DA concentrations were consistent across groups,
29.71 fmol/min (l-THP only), 28.43 fmol/min (l-THP +
Nic), 24.86 fmol/min (Nic only), 27.29 fmol/min (Bupro-
pion + Nic), and 27.57 fmol/min (Varenicline + Nic).
Nicotine (0.4 mg/kg, s.c.) and l-THP (5 mg/kg, i.p.)
Fig. 2 Comparison of pretreatments on nicotine reinstatement. All groups extinguished nicotine-seeking behavior when environmental cues as
well as nicotine were removed. Reinstatement consisted of pretreatment followed by a nicotine priming injection 5 min prior to the session as
well as reintroduction of the environmental cues associated with nicotine infusions. Nicotine was not available during reinstatement sessions. All
drug based pretreatments significantly reduced reinstatement responding from reaching nicotine baseline levels (Nic Baseline). All data is
presented as mean + S.E.M. comparisons are made against Nic Baseline within group, two-way ANOVA, n = 6 per group, *p < 0.05,
**p < 0.01, ***p < 0.001
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increased extracellular DA concentration from baseline in
the nAcb (Fig. 5a) p < 0.01. Area under the curve analysis
revealed that all compounds increased extracellular DA
concentrations from baseline, with bupropion treatment
having the most robust effect (Fig. 5b, see also Additional
file 1: Figure S5 and Figure S6). One-way ANOVA re-
vealed an effect of pretreatment F (4, 24) = 8.313, p <
0.001, with only bupropion pretreatment displaying sig-
nificant difference from other groups in Bonferroni post
hoc analysis (p < 0.01 bupropion-nicotine vs. nicotine only,
p < 0.05 bupropion-nicotine vs. l-THP only, p < 0.001
bupropion-nicotine vs. varenicline-nicotine). l-THP alone
did not significantly elevate DA concentrations from DA
concentrations measured when nicotine was administered
alone. However, l-THP administered before nicotine did
significantly increase DA concentrations in comparison to
DA concentrations measured when nicotine was adminis-
tered alone, t-test p < 0.01.
Discussion
Our study found that l-THP blocked the abuse-related
behavioral effects of nicotine in several rodent models.
l-THP decreased nicotine SA in experienced animals,
blocked combined cue and nicotine-induced reinstate-
ment of nicotine-seeking behavior, and attenuated nico-
tine induced hyperactivity. This study also demonstrated
Fig. 3 l-THP effect on nicotine-induced hyperactivity. l-THP displayed a protective effect against nicotine induced hyperactivity. In testing of
hyperactivity, all rats were pretreated with two injections of saline during the baseline phase. In the nicotine administration phase (Nic Admin) rats
were pretreated with their respective treatment before placement into chambers and treated with nicotine 5 min before placement into
chambers. a Total movements displayed over each session. All groups display similar movements from acclimation through pretreatment test.
When groups are given their respective pretreatments followed by nicotine, differences emerge between groups, significance is seen individually on
day 13 (Nic 6) *p < 0.05. b Hyperactivity testing collapsed by segment: Baseline, Nic Admin, or Nic Challenge. During the nicotine administration phase
rats pretreated with l-THP did not display hyperactivity compared to their respective baseline activity. Rats pretreated with saline did display
hyperactivity compared to their baseline. During the nicotine challenge (Nic Challenge) all rats received only one injection of nicotine (0.4 mg/kg s.c.)
5 min before placement into locomotor chambers. All rats displayed hyperactivity in this phase. Rats previously pretreated with l-THP who did
not display hyperactivity during the nicotine administration phase rebounded to display hyperactivity when l-THP was not presented before
nicotine. All data is presented as mean + S.E.M. Two-way ANOVA * denotes within group comparison to baseline, **p < 0.01, ***p < 0.001, +
denotes between group comparison of l-THP and saline during Nic Admin, student paired t-test, +++ p < 0.001, n = 8 per group
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neurochemical changes induced by l-THP administration
in the mesolimbic dopaminergic system. Taken together
this study adds knowledge to the current profile of l-THP
through demonstrating efficacious use of l-THP in the
treatment of drug addiction beyond heroin, cocaine, and
methamphetamine addictions. This study strengthens the
case for the development of l-THP into a clinical treat-
ment for nicotine addiction. The history of safe clinical
use in China along with the preclinical efficacy concerning
nicotine addiction displayed in the current study makes l-
THP a worthy candidate for development into a nicotine
cessation treatment.
The rewarding effect of nicotine addiction is difficult
to break, as annually only 3 % of smokers quit success-
fully [1]. Thus there is a drastic need for new efficacious
treatments that will enhance smoking cessation. Given
that reducing the rewarding value of nicotine can aid in
decreasing smoking in repeat users [25], l-THP appears
promising as a smoking cessation treatment. l-THP di-
minished the rewarding effects of nicotine in a dose
dependent manner, by reducing SA of nicotine in experi-
enced animals. The efficacy of l-THP is also comparable
to first line treatments for smoking cessation at their
optimum treatment doses and pretreatment times. The
dose of varenicline was chosen based on literature which
states a low dose (1 mg/kg) of varenicline with long pre-
treatment time (2-h) most effectively reduces animal
responding for nicotine [15]. The dose of bupropion was
chosen based on literature which states that a high dose
of bupropion (40 mg/kg) with a moderate pretreatment
time (30 min) is most effective in reducing animal
responding for nicotine [18]. The efficacy of l-THP in
Fig. 4 Locomotor and food behavioral control studies of l-THP. l-THP 3-5 mg/kg displayed no sedative effects on locomotor activity or responding for
food, all data is presented as mean + S.E.M. a In locomotor testing, rats were acclimated to locomotor chambers. Rats were then pretreated with saline
or l-THP 30 min before placement into locomotor chambers and treated with saline 5 min before placement into locomotor chambers. Rats were
trained under this protocol for six consecutive days. No significant difference was found in locomotor activity between saline and l-THP between the
doses of 3–5 mg/kg, n = 8 per group. b In food testing, rats were trained to respond in operant chambers under an FR 10, 20-s time out schedule for
sucrose pellets. Sessions lasted 1-h, once rats received the maximum number of pellets (40 pellets) for three consecutive sessions they were tested with
pretreatment of l-THP in escalating doses; at least five sessions of saline treatment were given between test doses. l-THP at 7 mg/kg and 9 mg/kg
significantly reduced the responding rate for sucrose pellets within the 1-h session, one-way ANOVA, ** p < 0.01, n= 10 per group
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reducing nicotine SA proved to be significantly greater
than the first line smoking cessation treatment vareni-
cline. Further, the consistency of l-THP pretreatment on
nicotine SA proved to be more stable than bupropion as
l-THP consistently decreased responding for nicotine
across each day of study, while the effect of bupropion
varied across each day of study. l-THP developed no tol-
erant effect on nicotine SA observed over three repeated
administrations. These data suggest that l-THP may sta-
bly reduce smoking in habitual smokers to a greater
degree than treatments that are currently available.
The efficacy of l-THP extends beyond primary reward
as assessed in nicotine SA studies. l-THP has been shown
to block or reduce the reinstatement of drug-seeking be-
havior induced by cocaine, heroin, or methamphetamine
[8, 19, 28, 34]. This utility of l-THP holds true concerning
nicotine addiction. We showed that combined cue and
nicotine-induced reinstatement was blocked by l-THP at
both tested doses. The efficacy of l-THP was greater than
the efficacy of both varenicline and bupropion. Favorable
reinstatement data suggest that l-THP may be efficacious
in the prevention of nicotine relapse in the clinical setting.
Given that relapse is a major obstacle to remaining nico-
tine free, as 80 % of smokers who attempt to quit without
assistance return to smoking within a month [1], the abil-
ity of l-THP to thwart combined cue and nicotine induced
reinstatement is a much needed quality in a smoking ces-
sation treatment.
Beyond SA and reinstatement, l-THP displayed utility
in attenuating behavioral effects associated with nicotine
Fig. 5 Microdialysis studies of treatment effects on DA release in nAcb. All compounds increased extracellular DA concentrations from baseline
within the nAcb. Microdialysis was performed in awake, freely moving rats. Baseline measures were taken in each rat until three consecutive basal
DA samples displayed less than 17 % variance. Rats were then pretreated with their respective compounds. Samples were taken every 20 min for
180 min after nicotine administration (or l-THP administration when only l-THP was given), all data is presented as mean + S.E.M. a Effect of
nicotine or l-THP on extracellular DA concentration in nAcb. Both compounds significantly increased DA concentration from baseline within the
nAcb, one-way ANOVA **p < 0.01. b Area under the curve (AUC) analysis and comparison of pretreatments to area under the curve of nicotine
treated rats (AUC collected from time of pretreatment to 60 min after nicotine was administered). The l-THP only group is displayed to show a
comparison of changes in extracellular DA concentration caused by l-THP under nicotine-free conditions within the same 60 min time frame.
l-THP pretreated rats who received nicotine and bupropion pretreated rats who received nicotine had significantly higher AUCs than rats receiving
nicotine alone. Bupropion pretreated rats receiving nicotine had the highest AUC, one-way ANOVA * denotes comparison to nicotine only
group, # denotes comparison to l-THP-Nic group, **p < 0.01, # p < 0.05, n = 4–6 per group
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sensitization. Hyperactivity can result from the psychos-
timulant effects of nicotine. l-THP, however, was able to
attenuate this effect, blocking hyperactivity from occur-
ring when administered before nicotine. This effect of
l-THP displays its utility in treating behavioral compo-
nents of nicotine sensitization. Thus, l-THP is effective
against the centrally-mediated effects of nicotine which
manifest as drug-seeking behavior and hyperactivity.
Clinical studies are needed for validation of l-THP ef-
fects on both drug seeking and hyperactivity in humans.
We believe l-THP may also reduce anxiety in the clin-
ical setting given that l-THP has been found to alleviate
anxious behavior as tested via elevated plus maze and
open-field testing [16] in preclinical models. If trans-
lated into the clinical setting, reduced anxiety may
mean reduced nicotine use and relapse, as smokers are
noted to return to smoking in order to reduce anxiety
[1, 11].
Our current study dose of l-THP is selective to the
abuse-related effects of nicotine. l-THP, at doses that
blocked nicotine’s effect, did not affect food-maintained
behavior and had no sedative effect on locomotor activ-
ity. Furthermore, our maximally effective dose of l-THP
(5 mg/kg) is below the reported doses of l-THP used for
blocking effects on other drugs of abuse. For example, l-
THP has been used for treatment of cocaine addiction at
doses up to 20 mg/kg [19, 31] and methamphetamine
addiction at doses up to 10 mg/kg [28] in pre-clinical
testing without detriment to animal health. This com-
parison demonstrates that l-THP is safely tolerated at
the doses used in the current study. Clinical testing is
needed to determine the ideal dosing parameters in
humans.
Microdialysis studies were not meant to correlate
onto behavioral studies, but to independently examine
and compare neurochemical changes as a result of l-
THP administration, nicotine administration, or com-
bined administration of treatments and nicotine. In
microdialysis studies both l-THP and nicotine inde-
pendently increased extracellular DA concentration
(in comparison to baseline) in the nAcb. The com-
bined administration of l-THP and nicotine also in-
creased extracellular DA concentration. This increase
was slightly greater than the dopamine increase in-
duced by the combined administration of varenicline
and nicotine, yet modest in comparison to the increase
induced with the combined administration of bupro-
pion and nicotine.
The finding of l-THP enhanced extracellular DA con-
centrations in microdialysis experiments is consistent
with previous literature [21, 31]. However these findings
seem counterintuitive given that l-THP is a DA receptor
antagonist and is not addictive; it is difficult to say with
certainty why these effects occur. We, however, believe
the antagonism of l-THP at multiple DA receptors, in-
cluding D1, D2 and D3 play a vital role. l-THP’s effect on
extracellular DA concentration is likely due to its bind-
ing to D2 autoreceptors. It has been reported that l-THP
increases cocaine-enhanced DA within the nAcb in a
similar manner to D2 or D3 antagonists [26, 31, 32], sug-
gesting l-THP’s activity at D2 autoreceptors may incite
the release of extracellular DA within the nAcb. Block-
ade of autoreceptors on the presynaptic neuron would
result in disinhibition and the continued release of DA
from the presynaptic neuron resulting in accumulation
of DA within the synapse. This accumulation of DA
could explain the increased extracellular DA concen-
trations measured in microdialysis. Clinically, the
overall increase in extracellular DA concentration
within the nucleus accumbens as a result of l-THP ad-
ministration may contribute to alleviation of the hypo-
dopaminergic state that is associated with withdrawal
symptoms [1, 3, 10, 14]. This may prove to be a mechan-
ism through which l-THP is efficacious in the treatment
of drug addiction. Further investigation with l-THP is
needed to verify this potential effect. Concerning the anti-
addiction effects of l-THP, it is suggested that the binding
of l-THP to multiple DA receptor subtypes, as well as its
activity at other monoamine receptors may drive its thera-
peutic effects while inhibiting side effects [31]. The broad
activity of l-THP upon binding multiple receptors allows
for the modification of various monoamine systems.
Specifically, secondary actions at 5-HT and alpha ad-
renergic receptors may decrease extrapyramidal effects
associated with traditional DA receptor antagonists
[30]. Thus, l-THP has the unique potential to be devel-
oped into a treatment with dual capacity, reducing the
rewarding pleasure of nicotine and attenuating with-
drawal from nicotine with minimal side effects.
Despite the results of the current study, the exact
mechanism of action for l-THP is still widely unknown.
Unlike traditional DA antagonists used pharmacologic-
ally, the affinity of l-THP to DA receptors is modest,
displaying ki values of 124 nm, 388 nm, and 1420 nm
for D1, D2, and D3 receptors respectively [30]. Further,
the preferential binding of l-THP to D1 over D2, and D3
receptors separates it from previously studied DA antago-
nists (ex. Haloperidol), thus l-THP and its pharmaco-
logical effects are unlike previously studied compounds.
Conclusions
This study demonstrates the efficacy and unique neuro-
chemistry of l-THP concerning nicotine addiction. This
study does not elucidate the exact mechanism under-
lying the efficacy of l-THP in the treatment of nicotine
models of addiction; however, it provides evidence for
the continued development of l-THP into a treatment
for nicotine addiction. Future studies may involve testing
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of l-THP preclinically on varying doses of nicotine as
well as progressive ratio self-administration experiments.
Future clinical studies with nicotine are also in need for
further development of l-THP into a treatment for nico-
tine addiction.
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